Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Large Decrease in Short Interest

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a significant drop in short interest in the month of October. As of October 30th, there was short interest totaling 22,618 shares, a drop of 85.8% from the October 15th total of 159,295 shares. Approximately 1.7% of the shares of the company are short sold. Based on an average daily trading volume, of 48,253 shares, the days-to-cover ratio is currently 0.5 days.

Enlivex Therapeutics Trading Down 1.2%

NASDAQ:ENLV traded down $0.01 during trading hours on Thursday, reaching $1.25. 20,700 shares of the company were exchanged, compared to its average volume of 24,597. The firm has a market cap of $1.90 million, a PE ratio of -0.01 and a beta of 1.63. Enlivex Therapeutics has a twelve month low of $1.18 and a twelve month high of $434.40. The stock’s 50-day moving average is $7.13 and its 200-day moving average is $130.20.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ENLV. Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. Weiss Ratings restated a “sell (d)” rating on shares of Enlivex Therapeutics in a research report on Tuesday, September 22nd. Finally, Zacks Research cut Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $4,800.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. WINTON GROUP Ltd acquired a new position in shares of Enlivex Therapeutics during the second quarter valued at approximately $55,000. Susquehanna International Group LLP boosted its stake in shares of Enlivex Therapeutics by 1,428.5% in the second quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock worth $87,000 after acquiring an additional 147,334 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Enlivex Therapeutics by 53.2% in the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after acquiring an additional 45,303 shares during the last quarter. 1.02% of the stock is owned by hedge funds and other institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore balance to dysregulated immune responses. The company’s approach is intended to address conditions in which excessive or uncontrolled inflammation contributes to disease progression. Enlivex’s lead product candidate is Allocetra-OTS, an off-the-shelf cell therapy made from apoptotic cells. The therapy is designed to reprogram the immune system toward a balanced state by helping regulate the activity of immune cells, including macrophages.